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Abstract
Background: Safety assessment of genetically modified organisms is currently often performed by comparative
evaluation. However, natural variation of plant characteristics between commercial varieties is usually not
considered explicitly in the statistical computations underlying the assessment.
Results: Statistical methods are described for the assessment of the difference between a genetically modified
(GM) plant variety and a conventional non-GM counterpart, and for the assessment of the equivalence between
the GM variety and a group of reference plant varieties which have a history of safe use. It is proposed to present
the results of both difference and equivalence testing for all relevant plant characteristics simultaneously in one or
a few graphs, as an aid for further interpretation in safety assessment. A procedure is suggested to derive
equivalence limits from the observed results for the reference plant varieties using a specific implementation of the
linear mixed model. Three different equivalence tests are defined to classify any result in one of four equivalence
classes. The performance of the proposed methods is investigated by a simulation study, and the methods are
illustrated on compositional data from a field study on maize grain.
Conclusions: A clear distinction of practical relevance is shown between difference and equivalence testing.
The proposed tests are shown to have appropriate performance characteristics by simulation, and the proposed
simultaneous graphical representation of results was found to be helpful for the interpretation of results from a
practical field trial data set.
Background
Biotechnology has developed to allow the production of
genetically modified organisms carrying specific charac-
teristics of interest. For example, plants can be made tol-
erant to a herbicide, thus facilitating traditional chemical
weed control, or can be induced to produce an insectici-
dal protein, thus reducing the need for external chemical
treatment. Because of its novelty, concerns exist regard-
ing the safety of genetic modifications (e.g. [1]).
In Europe, genetically modified organisms (GMOs)
and derived products are allowed on the market after
passing an approval system in which the safety for
humans, animals and the environment is assessed. This
safety assessment is performed by the GMO Panel of
the European Food Safety Authority (EFSA), that has
issued guidance for applicants who seek to bring GMOs
onto the European market [2]. These guidelines advo-
cate a risk assessment strategy known as the compara-
tive approach [3,4]. Comparative risk assessment is
based on the idea that typically there are organisms that
a r ev e r ys i m i l a rt ot h eG M O ,w h i c hh a v eah i s t o r yo f
safe use as foods. Such organisms can be used as com-
parators for the GMO, and the purpose of the compara-
tive analysis is to identify similarities and differences
between the GM crop-derived food/feed and its non-
G Mc o u n t e r p a r t s .I nt h ef i r s ts t e pa g r o n o m i ca n dm o r -
phological characteristics of plants are considered as
well as their chemical composition. The general idea is
that a comparative risk assessment can establish equiva-
lence between the GMO and its non-GM counterpart
for characteristics other than the intended effects of the
genetic modification. Equivalence in this context is
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due to natural biological variation. However, little gui-
dance is available how to perform equivalence testing
for GMOs in practice. Although the EFSA Guidance
Document [2] discusses general principles for risk
assessment and recommends the use of appropriate sta-
tistical tools, detailed protocols for the design of experi-
ments and statistical analysis are not provided.
In practice, applicants have been using widely differing
protocols to carry out field trials and very different mod-
els for the statistical analysis (e.g. [5-10]). Oberdoerfer
et al. [5] applied equivalence tests using fixed but arbi-
trary equivalence limits of ± 20%. In a later paper by
Hothorn and Oberdoerfer [6] this fixed value was
described as rigid and not reflecting the difference in
variability between components, and component-specific
safety ranges were proposed to be proportional to the
variance of the concurrent control in the same field trials,
which method ignores the amount of background varia-
tion found between commercial varieties. Hammond
et al. [7] and Park et al. [8] only applied difference tests,
which ignores the question which difference would be
relevant biologically. Special pleading for significant
results was needed in the first of these publications to
arrive at their conclusion that the GMO was as safe and
nutritious as reference varieties. McNaughton et al. [9]
and Herman et al. [10] adjusted p values of difference
tests using the False Discovery Rate method which is a
method developed for multiple difference tests. However,
this method is simply not appropriate in the context of
equivalence testing because it is only concerned with
false discoveries and not with false non-discoveries. In
any case, whatever the advantages and disadvantages of
the methods, the application of different statistical
approaches and models may lead to different conclusions
regarding the risk assessment of GMOs and derived
foods/feeds. Therefore a working group of the EFSA
GMO Panel investigated whether more detailed guidance
could be provided to applicants regarding the use of
appropriate statistical models for the analysis of the data
from field trials for compositional, agronomic and pheno-
typic studies and animal feeding trials, and regarding the
design of field trials. This paper is based on the report of
the working group [11], and is restricted to the statistical
analysis of data on the chemical composition of plants
obtained in field trials. We will not further discuss the
experimental design of such field trials (see [11]).
Whereas typically many plant characteristics are analysed
in such field trials, the scope of the statistical tests in this
paper is restricted to the analysis of single characteristics.
However, a simultaneous display of test results for multi-
ple plant characteristics is advocated.
Equivalence testing is commonly used in biomedical
and pharmaceutical statistics [12,13]. For example,
pharmacokinetic parameters of alternative drug formula-
tions have to be shown to be within a factor 1.25 of the
value for the reference drug. In words, the null hypoth-
esis of the equivalence test is (for the symmetric case)
“there is a difference between the GMO and its refer-
ence of a certain minimum size” against the alternative
hypothesis: “t h e r ei sn oo ro n l yas m a l ld i f f e r e n c e
between the GMO and its reference”.I nt h i st e s t i n g
procedure we need a significant result (rejection of the
null hypothesis) in order to conclude that the GMO and
the reference are equivalent. Thus there is a limited
Error I probability (a) that equivalence is concluded
whereas a difference larger than the limit value exists in
reality.
Specific questions exist for equivalence testing of
GMOs. First, how can equivalence limits for GMO
mean characteristics relative to reference mean charac-
teristics be defined given that no generally agreed
equivalence factor (such as 1.25) exists? Secondly, how
should equivalence limits be estimated given that appro-
priate data from field trials will describe typical biologi-
cal variation rather than the maximum allowable
variation? Thirdly, can the equivalence testing procedure
be adapted to the typical large biological variation
usually found in field studies?
Equivalence testing requires the determination of
equivalence limits to enable its implementation. For
each chosen characteristic, or for groups of them,
e q u i v a l e n c el i m i t sf o rt h et r u ed i f f e r e n c ea r ee f f e c t i v e l y
the limiting values for an acceptable difference. In this
paper we will determine equivalence limits as relative
deviations from the overall mean of the reference vari-
eties. In current practice, equivalence limits have almost
never been established satisfactorily before the experi-
ment. Therefore, we suggest that commercial reference
varieties are included in field experiments, to allow a
direct comparison with the GMO. As will be explained,
this can be seen as a test of the difference between
GMO and the population of commercial references. An
alternative view is that the reference varieties in the
experiment allow the estimation of equivalence limits,
which are subsequently used for assessing the equiva-
lence of the GMO. Inclusion of both the conventional
counterpart and reference varieties in field or animal
experiments for GMO safety testing is not new, and
papers on such experiments have been published (e.g.
[14-16]). However, as far as we know data from such
studies have not been used before for setting limits for
equivalence testing in the manner proposed here.
Results
Equivalence testing for GMOs
We developed a statistical methodology to assist in the
comparative risk assessment of GM crops. The novelty
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differences and similarities (equivalences). To detect
unintended effects, it is optimal to study the differences
of the GMO with its non-GM counterpart. However, to
assess similarities and equivalence, a characterization of
natural biological variability is needed. We propose that
the GMO can be viewed relative to the background var-
iation shown by common varieties (e.g. commercial vari-
eties) used as references. For this dual purpose of
difference and equivalence testing we propose the use of
field trials using not only the GM crop and its non-GM
counterpart, but also a range of reference varieties.
Designs using a wide range of varieties have been used
previously, showing that this is a feasible approach in
principle (e.g. [14-17]).
When testing for differences (proof of difference
approach) the null hypothesis and alternative hypothesis
are:
H
H
GC
GC
0
1
0
0
:
:




where ΔGC is the true difference on an appropriate
scale between the GMO and the conventional counter-
part. Student’s t-test is a common tool for simple com-
parisons, but for the statistical analysis of data from
more complicated designs linear mixed models are
appropriate, as are also used in this paper (see Methods
section). For testing statistical significance of differences
an alternative procedure is to construct a confidence
interval for the difference, and observe whether this
includes the value zero. This method is preferred
because it gives the bonus of a quantification of the esti-
mated difference and its uncertainty.
A statistically significant test result identifies a differ-
ence, whether it is biologically relevant or not. More-
over, whereas for tests with confidence level 1-a there is
a limited Error I probability (a)t h a tas i g n i f i c a n tr e s u l t
is obtained (i.e. a difference is found) whereas no differ-
ence exists in reality, these tests do not restrict the
Error II probability (b) of finding no significance
whereas in reality there is a difference. So the absence
of a significant difference is not a proof for equivalence
of the GMO and the counterpart, or ‘’absence of evi-
dence is not evidence of absence’’ [18,19]. This moti-
vates supplementing the difference test with an
equivalence test.
For equivalence testing the state of non-equivalence
needs to be put as a null hypothesis, thus assigning the
restricted Error I probability a of the test to the event
of falsely declaring equivalence (rejecting the null
hypothesis of non-equivalence). This requires the use of
equivalence limits as maximum acceptable deviations
because the simple inequality Δ≠0d o e sn o tq u a l i f ya sa
testable hypothesis. Thus, when testing for equivalence
of a GMO and a reference the null and alternative
hypotheses become:
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where ΔGR i st h et r u ed i f f e r e n c eb e t w e e nt h eG M O
and the reference, and where EL is the equivalence limit
for this difference. Note that the hypotheses above
assume symmetrical lower and upper equivalence limits
(ELL =- EL and ELU =- EL), but this can be easily gener-
alised if needed. Using this set of hypotheses it can be
seen that the observed difference between GMO and
reference mean should be small to reject the null
hypothesis (and therefore accept the alternative state-
ment of equivalence). Large differences will not lead to
significant test results (and therefore the statement of
non-equivalence cannot be rejected in those cases).
With prior specified equivalence limits, both the dif-
ference test and the set of equivalence tests can be
implemented using a single confidence interval. This is
in the spirit of the two one-sided tests (TOST) approach
of Schuirmann [20]. Both implied null hypotheses of
non-equivalence (H0: ΔGR ≤ -EL and H0: ΔGR ≥ EL)a r e
rejected if the confidence interval lies entirely between
the equivalence limits. In equivalence studies the choice
of a 90% confidence interval is customary [12,13] as it
corresponds with the customary 95% level for statistical
testing of equivalence. However, it should be stressed
that preference for specific levels of confidence is not a
statistical decision, but one to be made by risk man-
agers. For simplicity of the approach we nevertheless
propose to calculate by default two-sided 90% confi-
dence intervals rather than calculating confidence inter-
vals separately with different confidence levels for the
difference and the equivalence tests. This proposal
implies that each (two-sided) difference test will have a
90% confidence level, and each equivalence test a 95%
confidence level.
The statistical procedure needed for GMO equivalence
testing is however more complicated than this. A single
test would be sufficient with fixed equivalence limits,
using e.g. a generally agreed equivalence factor (such as
1.25). Lacking this we estimate equivalence limits from
field studies with concurrent reference varieties, which
are typically the same studies in which also the GMO
and its non-GM counterpart are tested. We therefore
have a two-step procedure, at least in principle. The first
step is the setting of equivalence limits (step L), the sec-
ond step is their use for assessing equivalence (step E).
As practical limits on background variation we con-
sider appropriate percentiles (e.g. 2.5 and 97.5) of the
distribution of reference variety characteristics as the
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estimated equivalence limits in step L are always uncer-
tain. In principle, equivalence limits could be calculated
in one of the following three ways: 1) as point estimates
of the true equivalence limits; 2) as ‘inner’ confidence
limits (by setting them as the lower confidence limit on
the upper equivalence limit and the upper confidence
limit on the lower equivalence limit); or 3) as ‘outer’
confidence limits (the upper confidence limit on the
upper equivalence limit and the lower confidence limit
on the lower equivalence limit). In this paper the third
option is chosen, because typical variation between
reference varieties is smaller than maximum allowable
variation, which would ideally underlie the setting of
equivalence limits. Consequently equivalence limits
based on the typical variation between reference vari-
eties in the field trial are not true safety limits but only
specifications of limits on natural background variation.
Therefore their uncertainty can be allowed to be
included in the width of the equivalence interval as in
the chosen third option. The EFSA GMO Panel consid-
ered that specifying minimum requirements for the
experimental design [11] was enough to limit the inevi-
table estimation errors to reasonable levels.
The second step of the equivalence testing procedure
(step E) consists of comparing the GMO mean to the
equivalence limits obtained in step L. Again there are
three options for testing: (E1) direct comparison of the
point estimate for the GMO to the equivalence limits;
( E 2 )at r u et e s to fe q u i v a l e n ce (test the null hypothesis
that the GMO mean is outside the equivalence limits
against the alternative that it is inside them); and (E3) a
true test of non-equivalence (test the null hypothesis
that the GMO mean is inside the equivalence limits
against the alternative that it is outside them). Borrow-
ing some terminology from quality inspection theory
(e.g. [21]), test E2 controls the ‘consumer’s risk’ because
it has a limited probability of accepting non-equivalent
varieties, and test E3 controls the ‘producer’sr i s k ’
because it has a limited probability of rejecting accepta-
ble varieties. Test E1 will find ‘equivalence’ more often
than test E2 but less often than test E3, for which rea-
son we will refer to test E1 as a ‘shared risk’ test.
‘Shared’ here means that a borderline variety has a 50%
probability to be classified as either equivalent or non-
equivalent using this test procedure (as is confirmed by
simulation, see Table 1). We propose to classify the
results of test E1 as ‘e q u i v a l e n c em o r el i k e l yt h a nn o t ’
or ‘non-equivalence more likely than not’.
In traditional equivalence testing [12,13] E2-type tests
are being used. However, these may have a low power in
case of a large residual variation, which is typical for agri-
cultural field studies. Therefore, addressing our third
question (how to counter the problem of high variability),
it is proposed here not only to rely on test E2, but to
apply all three tests. This provides a richer view on
equivalence than obtained by using only one test. There-
fore the final outcome of the equivalence assessment is
not just binary, but it is one of four equivalence cate-
gories, for which we propose the following labels:
(i) equivalence; (ii) equivalence more likely than not;
(iii) non-equivalence more likely than not; and (iv) non-
equivalence.
The outcome of test E2 discriminates category
(i) from (ii)+(iii)+(iv). Similarly, the outcome of test E3
discriminates category (iv) from (i)+(ii)+(iii). The out-
come of test E1 discriminates (i)+(ii) from (iii)+(iv). In
the Method section exact calculations will be defined,
and it will be shown that the proposed test E1 applied
to estimated equivalence limits is actually just a test of
difference, with the null hypothesis that GMO and refer-
ence means are equal, but allowing for variability
between genotypes (which is the crucial difference with
the traditional difference test). On the other hand, tests
E2 and E3 are truly two-step procedures, where the null
hypothesis value of the test is only established after step
L. Consequently, statistical properties of such tests can
only be defined conditionally on the outcome of step L.
For the interpretation of results we recommend a gra-
phical display, similar to those suggested by others
[22,23]. However, certain adjustments are needed to
account for the fact that equivalence limits are estimated
values, and these are described in detail in the Methods
section. Figure 1 presents a schematic simplified exam-
ple of the display, showing the possible outcomes for a
single characteristic. For any given characteristic there
are then fundamentally seven possible types of outcome.
Among these seven types there are four where the mean
value of the GMO lies between the adjusted equivalence
limits (types 1-4), and three where it lies outside the
equivalence limits (types 5-7). It is assumed here that
the line of no difference is in between the adjusted
Table 1 Simulation results for various choices of true
GMO mean MG and true counterpart mean MC
MG MC power
test D
power
test E1
power
test E2
power
test E3
~ N(MR,V g) ~ N(MR,V g) 0.8289 0.9485 0.7603 0.0076
~ N(MR,V g)= M R (= 0) 0.7587 0.9481 0.7668 0.0091
~ N(MR,V g)= M G 0.1024 0.9496 0.7704 0.0076
MR+LSD(GR;2;95) ~ N(MR,V g) 0.9724 0.4957 0.0524 0.0523
MR+LSD(GR;2;95) = MR (= 0) 1.0000 0.4964 0.0551 0.0537
MR+LSD(GR;2;95) = MG 0.1006 0.4954 0.0514 0.0509
True reference mean MR = 0 in all cases. “~ N(MR,V g)” refers to a random
draw from a normal distribution with the specified mean and variance. LSD
(GR;2;95) refers to the theoretical least significant difference calculated using
equation 3 with theoretical variances and infinite degrees of freedom.
Number of iterations was 10,000. Values in bold can be compared to
theoretical values (0.1, 0.95, 0.5 or 0.05).
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counterpart is itself non-equivalent to the reference vari-
eties and a separate, non-statistical discussion should
consider the place and relative importance of difference
and equivalence testing in the risk assessment.
The results of the four tests are easily derived from
the graphical presentation as in Figure 1. The test of dif-
ference will give a significant result if the confidence
interval bar does not cross the line labelled “no differ-
ence”. Therefore in outcome types 2, 4, 6 and 7 there is
a significant difference between the GMO and the coun-
terpart. The test of equivalence consists of three subtests
as explained before. First, when the point estimate of the
GMO vs. counterpart difference falls within the adjusted
equivalence limits then the conclusion is that the GMO
variety is not significantly different from the reference
varieties and equivalence is more likely than not (out-
come types 1-4). Second, a stronger conclusion can be
given and the null hypothesis of non-equivalence will be
rejected (in favour of the alternative hypothesis of
equivalence) when the confidence interval bar falls
entirely within the adjusted equivalence limit lines (out-
come types 1 and 2). Finally, when the confidence inter-
val bar lies completely outside the adjusted equivalence
limits (outcome type 7), the null hypothesis of equiva-
lence can be rejected and the reasonable conclusion is
that of non-equivalence.
The interpretation of the outcome types 3-6 with
respect to GMO risk assessment may be more difficult
than for types 1, 2 and 7, and may need further safety
line of  
no  
difference 
adjusted 
upper 
equivalence 
limit
adjusted 
lower 
equivalence 
limit  
outcome 
type 
 
1  
2 
3  
4 
5 
6 
7 
(i) 
(ii) 
(iii) 
(iv) 
equivalence 
category 
Figure 1 Simplified version of a graph for comparative assessment showing the seven outcome types possible for each characteristic
analysed. After adjustment of the equivalence limits, a single confidence limit (for the difference) serves visually for assessing the outcome of
both difference and equivalence tests. Here, only the upper adjusted equivalence limit is considered. Shown are: the mean of the GMO
compared to the mean of the counterpart on an appropriate scale (square), its confidence interval (bar), a thick vertical line indicating zero
difference (for proof of difference), and thinner vertical lines indicating adjusted equivalence limits on the same scale (for proof of equivalence).
For outcome types 1, 3 and 5 the null hypothesis of no difference cannot be rejected: for outcomes 2, 4, 6 and 7 the GMO is different from its
counterpart. Regarding interpretation of equivalence, four categories (i) - (iv) are identified: in categories (i) and (iv) there is a significant
equivalence and non-equivalence, respectively, in categories (ii) and (iii) equivalence and non-equivalence, respectively, are more likely than not.
van der Voet et al. BMC Biotechnology 2011, 11:15
http://www.biomedcentral.com/1472-6750/11/15
Page 5 of 20evaluation, possibly using alternative statistical methods.
For example, if differences, even if not statistically signif-
icant, were consistent over multiple situations, this
could indicate the occurrence of unintended effects.
Outcome types 1 or 2 may easily be obtained for char-
acteristics that are stable and precisely measured within
each genotype, but that have a large natural variation
among reference genotypes. Outcome types 3 or 5 may
easily result when the measurement precision or within-
genotype stability is low in comparison to the natural
variation.
We propose to display as many of the analysed char-
a c t e r i s t i c sa si sf e a s i b l es i m u l t a n e o u s l y ,o nt h es a m e
graph (see the Results - Field trial example section).
More than one graph is required if characteristics are
analysed on different scales, and/or if some are trans-
formed and others not.
Testing the method by simulation
The performance of difference and equivalence tests was
investigated using simulation. The simulation settings
were based on the real field trial data (see Methods sec-
tion for details).
In the first simulation study (reported in Table 1,
upper part) the GMO mean was a random draw from
the same distribution as the reference varieties, thus
mimicking a stochastic equivalence between GMO and
reference varieties. When the counterpart mean was
chosen equal to the GMO mean, the theoretical size of
the difference test (0.1) was reproduced. When the
counterpart mean was a random draw from the refer-
ence distribution or was set equal to the reference
mean, there were almost always true differences between
GMO and counterpart, and these were detected with a
power around 80%. The performance of the equivalence
tests was independent of the choice of the counterpart
mean. Equivalence was detected with 95% probability
using test E1 and with 76-77% probability using test E2.
Non-equivalence was detected with less than 1% prob-
ability in test E3.
In the second simulation study (reported in Table 1,
lower part) the GMO was chosen at the border between
equivalence and non-equivalence, MR+LSD(GR;2;95)
(see Methods section for details). The border value
0.2407 on ln scale corresponds to a relative difference
between GMO mean and reference mean of 100*[exp
(0.2407)-1] = 27.2%. As in the first study the theoretical
size of the difference test (0.1) was reproduced when the
counterpart mean was chosen equal to the GMO mean,
and again, the results for the equivalence tests did not
depend on the choice of the counterpart mean. Under
this null-hypothesis both the proof of equivalence test
(E2) and the proof of non-equivalence test (E3) were
rejected in about 5% of the simulations, which is the
theoretical size of the tests. The shared risk test (E1)
accepted equivalence in 50% of the simulations, as
expected.
The results of the third simulation series are shown in
Figure 2. Here the GMO mean was varied systemati-
cally, deviating between dif =0 %a n ddif =6 5 %f r o m
the reference mean, and the counterpart mean was set
equal to the reference mean. For the case dif =0 %t h e
size of the difference test (0.10) is reproduced, in all
other cases there are true differences, and it can be seen
that the power of test D quickly rises to effectively 100%
at dif = 10%. Figure 2 also shows the behaviour of the
three equivalence tests. The proof of equivalence and
proof of non-equivalence tests (tests E2 and E3, respec-
tively) are seen to have the nominal size (0.05) at the
equivalence/non-equivalence borderline value dif =
27.2%. The equivalence test based on testing the differ-
ence between GMO and reference varieties, resulting in
a statement whether (non-) equivalence is more likely
than not (test E1) was not designed as a real proof of
equivalence test. As expected, test E1 has a probability
of 50% to conclude equivalence for dif = 27.2%. In com-
parison to test E2 it has higher power to find true
equivalence, but of course pays for this by also having a
larger probability to state ‘equivalence more likely than
not’ when in fact there is non-equivalence. Finally, it
can be noted that between 5% and 25% the GMO is still
often found to be equivalent to the reference varieties,
although it is very likely that at the same time a signifi-
cant difference with the conventional counterpart is
found.
Field trial example
The proposed methods are illustrated by an example
u s i n gr e a ld a t ap r o v i d e db yE F S A .S i n c et h i sp a p e ri s
not intended to contribute to the risk assessment of spe-
cific cases, the data are presented anonymously (see
Methods section for details). The precise calculations
are described in the Methods section. A graphical over-
view of the results of the comparative analysis is shown
in Figures 3 and 4. More detailed results are given in
Figure 5, and in Tables 2 and 3.
Figures 3 and 4 show the relative differences of the
GMO with respect to the conventional counterpart for
53 plant characteristics. For example, relative large
deviations are seen for acid detergent fiber (+10%), feru-
lic acid (-13%), folic acid (+14%), neutral detergent fiber
(+14%), niacin (-13%) and total dietary fiber (+12%).
However, depending on the variability and uncertainty
underlying them, large differences may not be statisti-
cally significant (e.g. the interval for acid detergent fiber
includes 1, so the difference is not significant), while
smaller differences may be (e.g. glycin is significantly
higher in the GMO than in the counterpart, with a
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Page 6 of 20point estimate of only +3.5%). Note that the significance
tests are based on a standard error of difference (see
Table 3) which is calculated from the residual variance
Vε (see Table 2) as sed V GC;1
1
12
1
10    ,w h e r e1 2
and 10 are the number of replications in this experiment
for GMO and counterpart, respectively. The number of
degrees of freedom, estimated by the Kenward-Roger
method, varies between 38.7 (16:1 palmitoleic) and 54.6
(ash).
In total there were twenty-three analytes with a signif-
icant difference between GMO and counterpart (which
is 43% of the 53 investigated analytes). These analytes
are shown in blue (or in black or red if there was also a
potential equivalence problem) in Figures 3 and 4, and
some examples of boxplot representations [24] of these
data are shown in Figure 5 to assist further interpreta-
tion. Note, however, that these boxplot representations
ignore some aspects of the model, such as site and repli-
cation variation. Therefore, the boxplots alone cannot
provide a complete overview.
The variation between reference varieties has been used
to calculate equivalence limits. Although conceptually
there is just one set of equivalence limits, the limits were
calculated on three different scales. Each scale is useful
for a specific purpose.
1 .T h ef i r s ts c a l ei st h en a t u r a ls c a l ew h i c ha l l o w s
food/feed experts to recognize values most easily. For
instance, niacin has an equivalence interval [16.1, 27.1]
when back transformed on this natural scale. These
intervals are shown in the boxplots (Figure 5).
2. The second scale is the ratio scale where the GMO
is compared to the mean of the reference varieties (see
Table 3). This scale provides the most direct view
whether the difference between GMO and references is
significant (it is significant if the interval does not con-
tain the value 1). This scale is therefore best for distin-
guishing between equivalence categories (ii) and (iii)
(test E1). For niacin the equivalence interval on this
scale is [0.59, 0.99], so indeed the difference is signifi-
cant and non-equivalence is more likely than not.
3. Finally, the equivalence interval can be expressed on
the adjusted scale where both GMO and references are
compared to the conventional counterpart (see Figures 3
and 4); this scale allows a simultaneous presentation of
the results for both the comparison of GMO with the
Power and size of tests
0
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Deviation GMO from reference and comparator means (%)
P
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o
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i
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equiv. test E1
equiv. test E2
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diff. test D
Figure 2 Results of the simulation study. Power of difference and equivalence tests as a function of relative difference dif = 100*[exp(d)-1],
where d is the difference on ln scale. For dif = 0 the reported power is also the size of the difference test D. For dif = 27.2% the reported
power is also the size of equivalence tests E2 and E3.
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Page 7 of 20counterpart and the comparison of GMO with the refer-
ence lines. Therefore it is the easiest scale for performing
a test of equivalence by the graphical equivalent of the
TOST procedure advocated in this paper (see Figures 3
and 4). For the example of niacin the equivalence interval
on this adjusted scale is [0.88, 1.20]. This interval over-
laps with the confidence interval for the comparison of
the GMO with its counterpart (which is [0.84, 0.90], see
Table 3), therefore neither equivalence nor non-equiva-
lence has been proven for this analyte (tests E2 and E3).
In any case, the three intervals are just adjusted ver-
sions of each other and completely equivalent for statis-
tical testing as explained more fully in the Method
s e c t i o n .I nt h ec u r r e n te x a m p l et w oc a s e sw e r ef o u n d
where, on applying test E1 the GMO point estimate falls
outside the calculated equivalence limits, or, in other
words, there was a statistically significant difference
between the GMO and the references (16:0 palmitic and
niacin). For these analytes non-equivalence is more
likely than not. For further interpretation boxplots are
Figure 3 Part 1 of example comparative analysis. Circles and bars represent point estimate and 90% confidence interval for ratio GMO to
counterpart (here termed comparator). Diamonds represent adjusted equivalence limits based on reference varieties. Colours represent different
types of outcome, cf. Figure 1. Green: 1; Blue: 2; Black: 3-4 and cases with genotype variance (Vg) estimated zero; Red: 5-7.
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Page 8 of 20given in Figure 5. It can be seen that for 16:0 palmitic
both the GMO and the counterpart are higher than the
reference range, therefore on this single characteristic
GMO and counterpart seem to present the same
hazards, if any. It is outside the scope of this document
to discuss the risk assessment of such cases. For niacin
the situation is different. Niacin is found 24% lower in
the GMO than on average in the reference varieties, and
the result is also significantly lower (by 13%) than what
is found for the counterpart.
A problem occurs when the variance component
between reference genotypes is estimated as zero. In the
current example dataset this occurred with ash and phy-
tic acid. In these cases the calculation of standard errors
of difference will be based on the assumption that there
is no variation between the reference genotypes, and
standard errors and degrees of freedom are derived
from a model which omits the random factor for geno-
types. This is not a truly believable model: too many
degrees of freedom will be assigned to the standard
Figure 4 Part 2 of example comparative analysis. Circles and bars represent point estimate and 90% confidence interval for ratio GMO to
counterpart (here termed comparator). Diamonds represent adjusted equivalence limits based on reference varieties. Colours represent different
types of outcome, cf. Figure 1. Green: 1; Blue: 2; Black: 3-4 and cases with genotype variance (Vg) estimated zero; Red: 5-7.
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Page 9 of 20error of difference (see Table 3) leading to equivalence
intervals which are typically too narrow.
Accepting the calculated equivalence limits as null
hypothesis values in a test of equivalence for the remain-
ing 49 analytes leads to the conclusion that 44 are proven
to be equivalent to the reference varieties, whereas for 5
(lysine, phosphorus, potassium, vitamin B6 and vitamin
E) the equivalence is more likely than not, but not strictly
proven at the 95% confidence level. For further interpre-
tation boxplots can be given, see examples in Figure 5.
Discussion
Difference testing and equivalence testing can both con-
tribute to a meaningful comparative assessment. First,
the GMO can be different from its appropriate non-GM
counterpart, and a difference may constitute a hazard
(or potential risk) which should be subject to further
safety evaluation. This is why the proof of difference is
sometimes referred to as “proof of hazard”, but this is a
misleading term because there are many differences that
present no hazard for human health. Secondly, a GMO
can be equivalent to appropriate references, such as a
range of commercial varieties. Established equivalence of
a GMO has been interpreted as relevant for subsequent
toxicological risk assessments. It should be stressed that
statistical approaches should never be used for auto-
matic decisions of food safety, but as tools providing the
appropriate context for the final safety assessement.
For testing of differences and equivalences two-sided
tests (both increased and decreased characteristics are
relevant) is the most common case, but if it is ap r i o r i
known that differences can only be in one direction,
then it can be easily adapted to one-sided versions
(looking only at increases or decreases).
Figure 5 Boxplot examples for selected analytes [24]. Each box extends from the lower to the upper quartile (p25 to p75) and the line in
the middle is the median (p50). The whiskers extend to extreme data points (minimum and maximum), unless points are farther away from the
quartiles than 1.5 times the box length, in which case the points are shown separately as crosses and the whiskers only cover the remaining
points. comp = comparator (conventional counterpart); gmo = GMO; ref = reference varieties. Additional thicker bars in the boxplot for
references represent geometric mean and calculated equivalence limits.
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Page 10 of 20Table 2 Geometric means for counterpart (Gmc = exp(mC)), GMO (Gmgmo = exp(mG)) and reference varieties (Gmref =
exp(mR)), and variance components for random terms in mixed model: genotype (Varg), site (Vars), replication within
site (Varr) and residual (Var0)
Analyte Gmc Gmgmo Gmref Varg Vars Varr Var0
16:0 Palmitic 0.396 0.409 0.296 0.01573 0.003597 0 0.003831
16:1 Palmitoleic 0.004 0.004 0.004 0.00982 0 0.000873 0.003754
18:0 Stearic 0.047 0.047 0.056 0.0274 0.000701 0.000814 0.00554
18:1 Oleic 0.871 0.935 0.812 0.03305 0.000298 0.000307 0.003484
18:2 Linoleic 1.512 1.492 1.675 0.01189 0.002407 0.000909 0.004923
18:3 Linolenic 0.034 0.031 0.034 0.01336 0.003134 0.00088 0.004658
20:0 Arachidic 0.013 0.013 0.013 0.01037 0.001517 0.000802 0.003484
20:1 Eicosenoic 0.011 0.011 0.01 0.01846 0.003502 0.000642 0.005708
22:0 Behenic 0.005 0.005 0.005 0.01075 0.002956 0.00046 0.002557
Acid Detergent Fiber 3.52 3.884 3.523 0.0071 0.000355 0 0.027063
Alanine 6.172 6.366 6.999 0.01215 0.001757 0.001137 0.001974
Arginine 3.641 3.816 4.153 0.00264 0.00029 0.000318 0.002505
Ash 1.13 1.167 1.27 0 0.005899 0.000455 0.010976
Aspartic acid 5.281 5.453 5.967 0.00774 0.000515 0.000592 0.001391
Calcium 51.015 49.108 42.441 0.02556 0.012244 0 0.004253
Carbohydrates 75.683 75.084 74.458 0.00006 0.000177 6E-07 0.000041
Copper 1.161 1.242 1.322 0.03896 0 0 0.009164
Cystine 1.699 1.689 1.819 0.00544 0.000305 0.001014 0.001862
Ferulic acid 2008 1747 1841 0.01331 0.00426 0.000544 0.008106
Folic acid 0.543 0.618 0.573 0.01341 0 0.001377 0.079694
Glutamic acid 15.536 16.056 17.57 0.01474 0.001769 0.00147 0.00226
Glycine 3.063 3.172 3.395 0.00243 0.00023 0.00041 0.001327
Histidine 2.389 2.452 2.63 0.00656 0 0.000705 0.001949
Iron 17.11 16.539 18.846 0.01445 0.01215 0 0.009386
Isoleucine 2.747 2.869 3.088 0.01289 0.000131 0.00151 0.00289
Leucine 10.231 10.562 11.57 0.01851 0.004143 0.001788 0.002688
Lysine 2.602 2.715 2.925 0.00074 0.00018 0 0.002259
Magnesium 1060 1104 1144 0.00672 0.000345 0.000045 0.001882
Manganese 6.377 6.705 6.67 0.03391 0.002448 0.000885 0.003924
Methionine 1.767 1.718 1.889 0.01255 0.001974 0.001786 0.003079
Moisture 11.94 12.093 11.973 0.00098 0.007057 0 0.000693
Neutral detergent fiber 8.629 9.826 9.166 0.00409 0.00175 0.001613 0.015329
Niacin 18.241 15.9 20.915 0.01264 0.002064 0.000351 0.002513
p-coumaric acid 154.5 147.9 165.5 0.05678 0.00603 3.46E-05 0.011303
Phenylalanine 4.102 4.255 4.631 0.0145 0.002208 0.001255 0.001975
Phosphorus 2799 2804 3177 0.00427 0.002569 0 0.002005
Phytic acid 0.57 0.523 0.658 0 0.000268 0.009507 0.031919
Potassium 3242 3171 3604 0.00313 0.008 0 0.001503
Proline 7.29 7.69 7.997 0.01372 0 0.002004 0.002592
Protein 8.222 8.449 9.132 0.00878 0.000437 0.000713 0.001314
Raffinose 0.113 0.118 0.09 0.04279 0.017792 0 0.028393
Serine 4.119 4.242 4.628 0.00901 0.003357 0.00139 0.002331
Threonine 2.724 2.858 3.046 0.00621 0 0.000773 0.002362
Total dietary fiber 11.448 12.801 12.301 0.00545 0.00252 0.000949 0.015822
Total fat 2.979 3.138 3.038 0.01024 0.001744 0.000382 0.002228
Tryptophan 0.481 0.505 0.543 0.00176 0.000333 0.000318 0.004406
Tyrosine 2.674 2.768 3.152 0.01124 0.003216 0.000612 0.01474
Valine 3.739 3.902 4.239 0.00793 0 0.000922 0.002064
Vitamin B1 0.344 0.352 0.352 0.00844 0.00015 0.000611 0.003195
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Page 11 of 20Not always will there be datasets from field trials with
reference varieties in their trial design. Use of literature
data may occasionally be considered as an alternative
source for quantifying background variation, but may
present great difficulties both regarding the representa-
tivity of the data and the possibilities to discern the dif-
ferent components of variation. Further discussion is
given in [11].
We described how the simultaneous application of dif-
ference and equivalence testing can lead to seven possi-
ble types of outcome (see Figure 1). With respect to the
necessity of further evaluation to assess a possible
impact of GMOs on human/animal health, the patterns
of significant differences (Types 2, 4, 6, 7) should be
inspected for biologically relevant signals. Cases with a
clearly established non-equivalence in test E3 (Type 7)
and cases where non-equivalence is found more likely
t h a nn o ti nt e s tE 1( T y p e s5 ,6 )r e q u i r ef u r t h e re v a l u a -
tion. Risk assessors may also require further evaluation
for cases where equivalence is more likely than not
according to test E1, but not significant in the formal
equivalence test E2 (Types 3, 4). Risk characterization
will then be used by assessors to specify what further
evaluation is needed, based on considerations linked to
patterns of observed results and biological or toxicologi-
cal relevance.
Experiments should be designed to have sufficient sta-
tistical power to be able to reject the null hypotheses
being tested for relevant magnitudes of effect. However,
the use of observed power, which is power estimated
from the data arising from the experiment itself, is not a
valid alternative. It has been proposed that equivalence
can be concluded for a non-significant difference, pro-
vided that the observed power of the difference test for
ad i f f e r e n c ea tt h ee q u i v a l e n c el i m i ti sa tas p e c i f i e d
high level. However, Tempelman [25] pointed out how
with those criteria a poorly executed experiment would
be rewarded a greater chance of concluding equivalence
than an experiment with a better precision. Power ana-
lysis must therefore be done prior to the experiment.
It can be noted that for difference and equivalence
testing approaches power analysis has a different pur-
pose. First, risk assessors should require that a difference
test will find true differences of a specified magnitude in
a substantial probability of cases (e.g. 80%). Secondly,
applicants for introducing a GMO on the market have
an interest that a truly equivalent GMO will pass the
equivalence test with high probability. This requires a
power analysis where the relevant effect level is for
example a zero or small difference between the GMO
and the mean of the reference varieties.
In this paper the focus is on comparing characteristics
averaged over environments. In the biomedical literature
on equivalence testing this is known as an approach for
average (bio)equivalence. Alternative approaches are
based on the idea of individual (bio)equivalence related
to the question of switchability of the treatments [12].
In the context of field trials this can be translated to
requiring equivalence in the population of environments
(sites). In the linear mixed model approach the genotype
by environment interaction would have to be estimated
[26], which is typically easy to do (see Methods section
for details). However, the consequences for safety assess-
ment are still unclear, for example would it be possible
to declare a GMO equivalent in some environments and
not in others? More discussion on such issues is needed
before a statistical approach can be devised.
Commercial reference varieties have also been
included in animal feeding studies (e.g. [8,12,27,28]). In
principle our proposed method can be used there as
well. However, when it is expected that the investigated
characteristics (such as animal blood and urine para-
meters) do not vary at all between reference varieties
used in the feed, this would not conform to the basic
idea proposed here of using observed variation between
genotypes as a basis to determine equivalence limits.
Further research on such cases is needed.
The method proposed in this paper may contribute to
an objective and transparent process of risk assessment.
However, several issues remain to be solved. First, the
approach should be adapted for data which cannot read-
ily be transformed to normality, such as counts, quantal
or ordinal data. Second, research is needed for the power
analysis of mixed model tests. More research is needed to
characterize the coverage probability of the estimated
confidence intervals for small sample sizes, such as three
plots, two years, and four sites, because the available
models are asymptotic. Moreover, research is needed for
an optimal design, i.e. optimal numbers of plots and sites
for a most powerful decision on equivalence. Statistical
Table 2 Geometric means for counterpart (Gmc = exp(mC)), GMO (Gmgmo = exp(mG)) and reference varieties (Gmref =
exp(mR)), and variance components for random terms in mixed model: genotype (Varg), site (Vars), replication within
site (Varr) and residual (Var0) (Continued)
Vitamin B2 1.177 1.103 1.221 0.00269 0.018009 0 0.007777
Vitamin B6 4.736 4.723 5.764 0.00946 0.009281 0.000296 0.002828
Vitamin E 0.006 0.006 0.009 0.02613 0.000318 0.000115 0.009676
Zinc 19.535 19.111 21.338 0.0136 0.001851 0.000192 0.003364
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Page 12 of 20Table 3 Assessment of differences and equivalences
GMO vs. counterpart GMO vs. reference mean
Analyte ratio dlow dupp sedGC;1 dfGC;1 ratio elow eupp sedGR;2 dfGR;2
16:0 Palmitic 1.034 0.9887 1.081 0.02658 49.3 1.3811 1.0317 1.849 0.1317 10.5
16:1 Palmitoleic 0.999 0.9558 1.045 0.02638 38.7 0.9982 0.7841 1.271 0.1055 8.4
18:0 Stearic 1.008 0.9538 1.066 0.03307 41.7 0.8355 0.57 1.225 0.1736 10.9
18:1 Oleic 1.074 1.0294 1.121 0.02538 42.1 1.1519 0.7595 1.747 0.1897 11.2
18:2 Linoleic 0.987 0.9366 1.04 0.03121 42.2 0.8908 0.6886 1.152 0.1155 10
18:3 Linolenic 0.904 0.8606 0.95 0.02942 39.9 0.9234 0.7009 1.216 0.1221 9.1
20:0 Arachidic 1.034 0.9906 1.079 0.02545 41.5 0.9931 0.7816 1.262 0.1075 10
20:1 Eicosenoic 0.995 0.9419 1.051 0.03253 41.4 1.11 0.8068 1.527 0.1432 10
22:0 Behenic 0.946 0.9117 0.981 0.0218 41.4 0.9766 0.7672 1.243 0.1089 10.4
Acid detergent fiber 1.103 0.9805 1.241 0.07046 51.9 1.1026 0.8373 1.452 0.1027 4.4
Alanine 1.031 0.9986 1.065 0.0192 41.4 0.9096 0.7052 1.173 0.1154 10.8
Arginine 1.048 1.0107 1.087 0.02153 41.9 0.9188 0.8077 1.045 0.0558 7.9
Ash 1.033 0.958 1.114 0.04498 54.6 0.9187 0.858
1 0.984
1 0.0341 53.6
Aspartic acid 1.033 1.0049 1.061 0.0161 41.4 0.9138 0.7455 1.12 0.0921 10.7
Calcium 0.963 0.9184 1.009 0.02801 48.5 1.1571 0.7993 1.675 0.1673 10.6
Carbohydrates 0.992 0.9875 0.997 0.00274 42 1.0084 0.9895 1.028 0.0083 8.2
Copper 1.069 0.9963 1.148 0.04221 51 0.9395 0.5947 1.484 0.2073 10.8
Cystine 0.994 0.9636 1.026 0.01863 40.1 0.9286 0.7797 1.106 0.0779 9.5
Ferulic acid 0.87 0.8132 0.931 0.04008 41.8 0.9489 0.7179 1.254 0.1234 9
Folic acid 1.138 0.929 1.395 0.12096 44.1 1.0786 0.6948 1.674 0.1515 3.6
Glutamic acid 1.033 0.9984 1.07 0.02055 41.4 0.9138 0.6908 1.209 0.127 10.9
Glycine 1.035 1.0084 1.063 0.01571 40.2 0.9343 0.8292 1.053 0.0525 8.8
Histidine 1.026 0.994 1.06 0.01903 40.7 0.9325 0.7711 1.128 0.0853 10
Iron 0.967 0.9015 1.036 0.04159 49.4 0.8776 0.6544 1.177 0.1288 8.6
Isoleucine 1.044 1.0045 1.086 0.0232 41.6 0.9292 0.7137 1.21 0.1192 10.5
Leucine 1.032 0.9942 1.072 0.02241 41.3 0.9129 0.6673 1.249 0.1422 10.9
Lysine 1.043 1.0084 1.08 0.02037 48.8 0.9282 0.8532 1.01 0.0322 4.7
Magnesium 1.041 1.0089 1.074 0.01863 42.6 0.9647 0.796 1.169 0.0863 10
Manganese 1.051 1.0047 1.1 0.02702 41.1 1.0053 0.6585 1.535 0.1922 11
Methionine 0.972 0.9338 1.012 0.02398 41.1 0.9095 0.7004 1.181 0.1177 10.3
Moisture 1.013 0.9938 1.032 0.0113 49.5 1.01 0.9357 1.09 0.0336 8.6
Neutral detergent fiber 1.139 1.0413 1.245 0.05322 43.2 1.072 0.8703 1.32 0.0778 4.4
Niacin 0.872 0.8405 0.904 0.0216 41.7 0.7602 0.5862 0.986 0.1178 10.8
p-coumaric acid 0.957 0.8867 1.034 0.04565 42.1 0.8938 0.5145 1.553 0.2498 10.6
Phenylalanine 1.037 1.0043 1.071 0.01921 41.4 0.9187 0.6965 1.212 0.1258 11
Phosphorus 1.002 0.9698 1.034 0.01923 48.5 0.8823 0.7537 1.033 0.0694 8.8
Phytic acid 0.919 0.8042 1.049 0.07949 53.2 0.7958 0.7082
1 0.894
1 0.0581 52.2
Potassium 0.978 0.9509 1.006 0.01665 47.9 0.8798 0.7675 1.009 0.0595 8.2
Proline 1.055 1.0166 1.095 0.02199 41.9 0.9616 0.7333 1.261 0.1227 10.7
Protein 1.028 1.001 1.055 0.01566 41.2 0.9252 0.7454 1.148 0.098 10.8
Raffinose 1.036 0.9177 1.17 0.07232 49.1 1.3123 0.7939 2.169 0.2218 8.9
Serine 1.03 0.9944 1.067 0.02087 41.1 0.9167 0.7343 1.144 0.0998 10.2
Threonine 1.049 1.0131 1.087 0.02094 41.5 0.9383 0.7788 1.13 0.0834 9.8
Total dietary fiber 1.118 1.0211 1.225 0.05404 41.2 1.0407 0.8284 1.307 0.087 4.7
Total fat 1.054 1.0181 1.09 0.02035 41.9 1.033 0.8173 1.306 0.1062 10.8
Tryptophan 1.049 1.0002 1.101 0.02851 44 0.9292 0.8205 1.052 0.0487 5.1
Tyrosine 1.035 0.9483 1.13 0.05215 44.4 0.8782 0.6674 1.156 0.117 7.3
Valine 1.043 1.0096 1.078 0.0196 41.8 0.9203 0.7477 1.133 0.0936 10.3
Vitamin B1 1.023 0.9818 1.065 0.02433 43.3 0.9999 0.8059 1.241 0.0972 10.3
Vitamin B2 0.938 0.8799 0.999 0.03784 49 0.9036 0.7671 1.064 0.0611 4.4
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Page 13 of 20analysis may need to be adapted to more complicated
designs (e.g. repeated measures). And last but not least,
t h e s em e t h o d sm a yb ea d a p t e dt ot h es i m u l t a n e o u s
assessment for multiple characteristics. When performing
many simultaneous tests spurious significant results can
be expected both in proof of difference and proof of
equivalence. There is little experience with multivariate
tests of equivalence (see e.g. [29-31]). Multivariate analy-
sis may give an alternative approach to the multiplicity
issue. Although some discussion of these issues is given
in [11], more research is needed.
Conclusions
Safety assessment of GMOsi su l t i m a t e l yac o m p l e x
undertaking in which the interpretation of composi-
tional data is only one element. And even in this
restricted setting the role of statistical methodology is
limited to provide a context for the final biological
interpretation of results. Nevertheless, this interpretation
can benefit from a standardised statistical approach that
clearly shows differences and equivalences in a compar-
able manner.
The main purposes of the comparative assessment are
twofold: to demonstrate whether the GMO and/or
derived food/feed is different from its appropriate non-
GM counterpart and/or to demonstrate whether it is
equivalent to appropriate reference varieties, apart from
the intended changes. This paper proposes a statistical
methodology that is not focussed exclusively on either
differences or equivalences, but that provides a richer
framework within which the conclusions of both types
of assessment are alloweds i m u l t a n e o u s l y .T h e
approaches are complementary: statistically significant
differences may point at biological changes caused by
the genetic modification, but which are not relevant
from the viewpoint of food safety. On the other hand,
equivalence assessments are used to classify differences
as being inside or outside the range of natural variation.
A procedure combining both approaches will aid the
subsequent interpretation of the statistical results.
A simulation study using realistic variance values vali-
dated the expected probabilities of the tests proposed.
An important conclusion is in a typical situation of vari-
abilities a range of deviations exists, say between 5% and
25%, where the GMO is still equivalent to the reference
varieties, although it is very likely to find a significant
difference with the conventional counterpart. This illus-
trates that the application of equivalence testing is a
useful complement to the traditional practice of per-
forming difference tests.
The conclusions drawn for the example field trial
dataset can be summarised as follows. For 23 out of 53
analytes there were statistically significant differences (at
the 90% confidence level) between GMO and counter-
part. The differences varied between -13% and +14%.
For two analytes, 16:0 palmitic and niacin, a statistically
significant deviation (at the 95% confidence level) from
the mean of the reference varieties was found, and non-
equivalence was more likely than not. Further evaluation
is required. For five analytes, lysine, phosphorus, potas-
sium, vitamin B6 and vitamin E, equivalence was more
likely than not, but a strict proof of equivalence cannot
be given. Further evaluation may be required. For two
analytes, ash and phytic acid, no proper conclusion on
equivalence can be formulated because of lack of obser-
vable natural variation in the reference varieties. Further
evaluation may be required. For 44 analytes (including
20 with significant differences between GMO and coun-
terpart) equivalence was established in a formal test of
equivalence (at the 95% confidence level) using the esti-
mated equivalence limits.
Methods
Linear mixed models
Measurements can be made on several scales (continu-
ous, ordinal, quantal, binary, count, multinomial). Here,
we focus on the continuous scale, which is appropriate
for most compositional, agronomic and phenotypic vari-
ables in field studies. For measurements made on other
scales it is often possible to devise similar statistical
approaches to those described here.
It is often appropriate to transform data before stan-
dard statistical methods are used. For example, many
biological effects are better described as multiplicative
rather than additive effects. Differences are commonly
expressed as a percent change, i.e. as relative differences
(ratios) rather than absolute differences. On the other
hand, most statistical models are additive models for
Table 3 Assessment of differences and equivalences (Continued)
Vitamin B6 0.997 0.9597 1.037 0.0229 41.6 0.8194 0.6529 1.028 0.1025 10.4
Vitamin E 0.953 0.8874 1.023 0.04217 42.5 0.6908 0.4718 1.011 0.1709 9.9
Zinc 0.978 0.9381 1.02 0.02495 42.5 0.8956 0.6814 1.177 0.1225 9.9
The 90% confidence limits (dlow, dupp) are expressed on the scale of ratio GMO to counterpart mean. seds are on ln scale, ratio and 90% confidence limits are
back-transformed. The 95% equivalence limits (elow and eupp) calculated on the scale of the ratio of GMO to reference mean. The point estimate of this ratio
itself is given in the column ratio. The width of the equivalence interval depends on sedGR;2 , given on the logarithmic scale, and the degrees of freedom for
equivalence (dfGR;2) calculated by the Kenward-Roger method. See text for further explanation.
1 For ash and phytic acid the equivalence intervals are not trustworthy, because the estimate of the variance between reference genotypes was 0 and sedGR;2 is
based on lower strata (note also the high values of dfGR;2 ).
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Page 14 of 20estimating or testing absolute differences. A logarithmic
transformation of the data may be appropriate because
it transforms a multiplicative model into an additive
model, and thus relative differences into absolute differ-
ences through the equation log(A/B)=l o g ( A)- log(B).
Only when reporting results (graphs, tables) can these
be back-transformed to the original scale. Here, we use
logarithmic transformations, but the appropriateness of
this should be investigated on a case-by-case basis for
other data.
Field experiments are usually replicated at multiple
sites. At each site a field trial is conducted with the vari-
eties randomised over plots in multiple blocks (or repli-
cations). The statistical analysis of data from the
experiments for comparative risk assessment is here
restricted to studying the average difference and the
average equivalence over sites. The primary objective for
an average difference/equivalence approach is neither
the identification of possible interactions nor per-site
(per-year) evaluation. Instead, overall (for all sites, plots,
years) confidence limits are estimated, allowing state-
ments on overall differences and equivalences.
A linear mixed model is used for the statistical analy-
sis of the data set (all sites and/or years) where the fac-
tors site and, if present, year are assumed to be either
random or fixed, depending on the details of the experi-
mental design. In this paper we assume random site
effects. The between-site, between-replicate, between-
plot and possibly the between-year variability will be
estimated as related variance components.
For the purpose of modelling the differences and simi-
larities from an experimental design with GMO, coun-
terpart and a range of reference varieties, it is useful to
describe the genotypes of the measured samples not just
by one factor, but by two factors and a dummy variable:
1. GenotypeGroup: a 3-level fixed factor distinguish-
ing GMO, conventional counterpart and the group
of reference varieties as a whole; note that this factor
includes the specific contrasts of interest between
GMO and its counterpart, and between GMO and
the group of references;
2. Genotype:ar a n d o mf a c t o rw i t ha sm a n yl e v e l sa s
there are varieties (GMO, conventional counterpart
and each of the reference varieties);
3. IndRef: an indicator variable with value 1 for the
reference varieties, and 0 otherwise.
By including the interaction of Genotype and the (uncen-
tered) indicator variable IndRef in a mixed model, the
GMO and its counterpart are not considered as levels of
the random factor. Therefore in such a model the
difference between the GMO and its counterpart and the
difference between the GMO and the mean of the reference
varieties, which are both specific contrasts of the fixed fac-
tor GenotypeGroup, will be assessed against the proper resi-
dual variation, excluding the variance between genotypes. If
on the other hand the indicator variable is omitted the resi-
dual variation will include the variance between reference
genotypes which is appropriate for establishing equivalence
limits from the full range of reference varieties. Note that in
neither of these models do the GMO and counterpart
means contribute to the residual variance component
because of the presence of the fixed factor GenotypeGroup.
I nt h ec a s eo ft h ee x a m p l ef i e l dt r i a ld a t at h el nt r a n s f o r m e d
data were thus analysed with two slightly different versions
of the mixed model, hereafter named model 1 and model 2,
respectively. For the tests of difference and equivalence:
yM e a n S i t e B l o c k
GenotypeGroup IndRef Genotype
ijkl i ij
kl l
  
   ijkl
(1)
and for establishing equivalence limits:
yM e a n S i t e B l o c k
GenotypeGroup Genotype
ijkl i ij
kl i j k l
  
 
(2)
where i, j, k and l are indices for site, block within
site, treatment group (counterpart, GMO or reference)
and reference varieties, respectively. The response yijkl is
the log-transformed result, using the natural logarithm
(ln). The fixed factors in this model are Mean, the over-
all mean, and GenotypeGroupk, the average deviation
from the overall mean for each of the three treatment
groups (k = 1: counterpart, 2: GMO, 3: reference geno-
types). The random factors in the model are Sitei,t h e
average deviation for site i, Blockij, the average deviation
for block j of site i, Genotypel, the average deviation for
reference genotype l, and εijkl, the residual term for each
measurement. As usual in mixed modelling, the random
terms are assumed to arise independently from normal
distributions with mean 0 and a certain variance compo-
nent that is to be estimated (Vs, Vb,V g and Vε, respec-
tively). A common way to fit mixed models to data is
the residual maximum likelihood (REML) algorithm,
which is available in all major statistical packages.
If it would be needed in addition to the average differ-
ence/equivalence approach of this paper, the site by gen-
otype interaction can be investigated by defining another
indicator variable, with value 0 for the reference vari-
eties, and 1 otherwise, and including its interaction with
GenotypeGroup as an additional fixed effect (uncen-
t e r e d )i nt h em o d e l .W ed on o tf u r t h e rp u r s u et h i s
model here (see Discussion section).
For comparing all tested varieties we need estimated
means, mC ,mG and mR (for counterpart, GMO and
references, respectively) and the standard errors of dif-
ference, sedGC;i and sedGR;i,w h e r ei is the model
adopted.
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models from standard software, they can also be written
out explicitly for both model 1 and model 2, at least
when the datasets are balanced (GMO, counterpart and
ng reference genotypes in nr replicates on ns sites):
sed
V
nn
GC
sr
;1 2   (3a)
sed V
V
nn
GC g
sr
;2 2 






 (3b)
sed
V
nn
V
n
V
nnn
GR
sr
g
gg s r
;1    (3c)
sed V
V
nn
V
n
V
nnn
GR g
sr
g
gg s r
;2     (3d)
Approximate two-sided 100(1-a)% confidence inter-
vals are based on the sedsa n dtdf;p ,b e i n gt h ep = 100
(1-a/2)% point of the appropriate Student’s t distribu-
tion, where df is the appropriate number of degrees of
freedom. For the calculation of df the method of Ken-
ward and Roger [32] has been recommended [33]. The
product tdf;1-a/2 sed is called the least significant differ-
ence (lsd) and may be obtained directly in some statisti-
cal packages. For the comparison between test materials
Xa n dYu s i n gm o d e lm (1 or 2) and one-sided confi-
dence percentage p we will denote this by lsd(XY;m;p).
The appropriate calculations to perform the difference
and equivalence tests are as follows:
1. For the test of difference (test D) calculate 90%
confidence limits as mG ±l s d (GC;1;95); when the
counterpart mean mC falls outside this confidence
interval the difference between GMO and counter-
part is statistically significant.
2. For the equivalence tests, calculate equivalence
limits ELL and ELU as 95% confidence limits around
the reference mean mR : mR ± lsd(GC;2;97.5).
3. When the GMO mean mG falls outside the equiva-
lence interval [ELL, ELU], the difference between the
GMO and the reference variety group is statistically
significant allowing for the background variation
between genotypes, and non-equivalence is more
likely than not (’shared risk’ test of equivalence E1).
4. For the tests of equivalence E2 (’proof of equiva-
lence’)a n dE 3( ’proof of non-equivalence’) calculate
90% confidence limits as mG ±l s d (GC;1;95). Equiva-
lence is proved using test E2 if this confidence
interval falls entirely within the equivalence interval
[ELL, ELU]. Non-equivalence is proved using test E3
if the confidence interval falls entirely outside the
equivalence interval [ELL, ELU].
All tests are performed on the logarithmic scale. For
interpretation of the numerical values, the means and
differences of means on the logarithmic scale can be
back-transformed to geometric means and ratios of geo-
metric means on the original scale. So, based on a dif-
ference D, the point estimate of the corresponding ratio
is e
D, and the approximate 100(1-a)% confidence inter-
val is e
D-lsd, e
D+lsd.
The practical implementation in two major software
packages for assessing the difference of the GMO to the
counterpart using model 1 (test D) is as follows (assum-
ing levels 1, 2 and 3 of the genotypegroup factor corre-
sponding to counterpart, GMO and references,
respectively):
Genstat:
FACTOR [labels=!T(compGMO,ref)]
ref_aside
CALC ref_aside = 1*(genotypegroup.in.!
(1,2))+\
2*(genotypegroup == 3)
VCOMPONENTS\
[fixed = ref_aside/genotypegroup; cad-
just = none]\
random = site + site.rep + genotype.
indref;\
constraint = pos
REML y
SAS:
proc mixed data = example CL = WALD alpha =
0.1;
class site rep genotype genotypegroup;
model y = genotypegroup/s
covb outp = out ddfm = kenwardroger;
random site site*rep indref*genotype;
estimate ‘gmo_comp’ genotypegroup -1 1 0/
CL;
run;
The practical implementation for estimating the
equivalence limits and for performing equivalence test
E1 using model 2 is as follows:
Genstat:
FACTOR [labels=!T(comp,GMOref)]
comp_aside
CALC comp_aside = 1*(genotypegroup == 1)+\
2*(genotypegroup.in.!(2,3))
VCOMPONENTS\
[fixed = comp_aside/genotypegroup]\
random = site + site.rep + genotype;\
constraint = pos
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SAS:
proc mixed data = example CL = WALD alpha = 0.05;
class site rep genotype genotypegroup;
model y = genotypegroup/s
covb outp = out ddfm = kenwardroger;
random site site*rep genotype;
estimate ‘gmo_ref’genotypegroup 0 1 -1/CL;
run;
For equivalence testing according to
tests E2 and E3, again using model 1, the
code is as follows:
Genstat:
FACTOR [labels=!T(comp,GMOref)]
comp_aside
CALC comp_aside = 1*(genotypegroup == 1)+\
2*(genotypegroup.in.!(2,3))
VCOMPONENTS\
[fixed = comp_aside/genotypegroup;
cadjust = none]\
random = site + site.rep + genotype.
indref;\
constraint = pos
REML y
SAS:
proc mixed data = example CL = WALD alpha =
0.1;
class site rep genotype genotypegroup;
model y = genotypegroup/s
covb outp = out ddfm = kenwardroger;
random site site*rep indref*genotype;
estimate ‘gmo_ref’ genotypegroup01- 1 /
CL;
run;
These program fragments give only the essential cen-
tral mixed model calculation. Obviously more program-
ming is needed for reading the data, outlier control,
data transformation, and post-processing the results to
calculate confidence intervals, equivalence limits and
plotting the graphs.
T h eb a s i ci n f o r m a t i o nn e e d e df r o mt h em i x e dm o d e l
are the means, the standard errors of difference and the
corresponding degrees of freedom. With the above two
specifications of the mixed model (either with Genotype
or with Genotype. IndRef among the random terms) the
means and variance components are exactly the same.
Only the sedsa n dt h edfs are different. Actually, from
equations (3) it follows that the seds from the two mod-
els 1 and 2 are related by:
sed sed V
sed sed V
GC GC g
GR GR g
;;
;;
2
2
1
2
2
2
1
2
2    
   
where Vg is the variance component estimate for the
background variation between the reference varieties.
Note that we need the sedGC;1 (so excluding genotypic
variation) for the GMO to counterpart difference test D,
and the sedGR;2 (including genotypic variation) for esti-
mating the equivalence limits and test E1. For equiva-
lence tests E2 and E3 we need both. Because of the
relations fitting either one of the models would be
enough to allow the calculation of both seds. The only
remaining reason for fitting two models rather than one
to the same dataset is the different calculation of the
degrees of freedom by the Kenward-Roger method in
the two cases.
Presentation of results
After the appropriate transformation, simultaneous dis-
play is facilitated by shifting all relevant values for each
particular characteristic to a scale that has mC,t h e
mean of the conventional counterpart for that character-
istic, as its baseline zero value. Therefore, on this new
scale, the values of the means of the GMO, its conven-
tional counterpart and the set of reference varieties,
become, respectively: mG - mC,0 ,mR - mC.N o t et h a ta
difference of 0 on an additive scale corresponds to a
ratio of 1 on a multiplicative scale. Hence, in principle,
for a multiplicative scale, both the mean of the GMO
and the equivalence limits can be displayed as ratios to
the counterpart (but see below for certain adjustments
required to achieve a valid practical outcome).
After shifting all relevant values to the new zero base-
line, the confidence limits for the difference test on this
new scale become: mG - mC ± lsd(GC;1;95), the equiva-
lence limits mR - mC ± lsd(GR;2;97.5), and the
confidence limits for the equivalence tests E2 and E3
mG - mC ± lsd(GR;1;95). Note that the equivalence lim-
its, chosen to be symmetrical around the centre of the
distribution of reference varieties, are typically asymme-
trical (before and after adjustment) on this new scale.
To facilitate visual interpretation, instead of using the
two sets of confidence limits in the graphs, it is recom-
mended for convenience that only one be displayed, that
for the difference test. Without some adjustment, the
confidence limits for the difference test would not give a
valid visual representation for the equivalence test on
the graph. This problem is overcome by making an
adjustment to the displayed equivalence limits. After
this adjustment the displayed confidence limits for the
difference test may be used as a basis also for the visual
representation of the equivalence test. In this way, one
confidence limit may serve visually for assessing the out-
come of both tests simultaneously. The adjustment of
the equivalence limits consists of two steps: (1) scaling
the basic equivalence limits, so that the confidence
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have the same width; and (2) an appropriate shift to
facilitate display of the adjusted limits, together with
mG, on the scale that has mC as its baseline zero value.
The adjusted equivalence limits for visual display are
calculated by the formula:
mm mm l s d G R
lsd GC
lsd GR
GC RG           (; ;. )
(; ; )
(; ;
29 75
19 5
19 5 ) )
Note that this adjustment is being made just for the ease
of visual display, and that the adjusted confidence limits
have exactly the same inclusion probability of 95% for the
true difference as the unadjusted confidence interval.
It is recommended that the graph should show the line
of zero difference between the GMO and its conventional
counterpart and, for each characteristic: the lower and
upper adjusted equivalence limits, the mean difference
between the GMO and its conventional counterpart, and
the confidence limits for this difference (see the set of
p o s s i b l ee x a m p l eo u t c o m e sf o ras i n g l ec h a r a c t e r i s t i ci n
Figure 1). The horizontal axis is labelled with values that
specify the change on the natural scale. In the case of a
multiplicative scale and a logarithmic transformation,
changes of 2 × and 1/2 × will appear equally spaced on
either side of the line of zero difference
Simulations
Simulation studies were performed to investigate how well
the difference and equivalence tests perform. Observations
were generated for 8 sites, 4 blocks per site and 8 geno-
types (GMO, counterpart and 6 reference varieties, repre-
senting commercial varieties in the real world) according
to a linear model for logarithmically-transformed observa-
tions. The model contained random terms for site, block,
genotype and plot (residual) drawn from normal distribu-
tions with mean 0 and variances equal to 0.0029, 0.0008,
0.0127 and 0.0073, respectively, which were the average
variance components found for 53 analytes in the field
trial example (see hereafter). For the 6 reference genotypes
independent random deviates were drawn from the geno-
type distribution with mean 0 and variance 0.0127.
In a first series of simulations the GMO mean was
considered exchangeable to the reference genotypes, and
therefore its value was set by making a draw from the
same normal distribution, with mean 0 and variance
0.0127. Three options for setting the counterpart mean
were investigated: a) equivalent to the reference mean
(its value was set by making another draw from this
same normal distribution); b) equal to the reference
mean (its value was set to 0); or c) its value was set
identically equal to the GMO mean.
In a second series of simulation the GMO mean was
set equal to the theoretical upper equivalence limit
calculated as described below. Again the same three
options for the counterpart mean were investigated.
In a third series of simulations the counterpart mean
was set to be equal to the reference mean (identically
equal to 0), and the GMO mean was varied systemati-
cally to investigate the power of the tests. Its value was
set equal to a value d (where d was varied systematically
between 0 and 0.5 (or, equivalently, the relative differ-
ence on the original scale dif = 100*[exp(d)-1] was var-
ied between 0% and 65%). Note that the choice d =0
corresponds to exact equality of GMO and counterpart,
whereas other choices lead to a true difference, though
not necessarily non-equivalence, because this depends
on what values the equivalence limits are set to.
Field trial data
The dataset analysed in this paper is an example of a
comparative assessment regarding GMO safety using
real data from a field study. We consider here 68 com-
positional characteristics of maize grain. Each character-
istic was measured on (i) a GM variety, (ii) a
conventional counterpart variety, and (iii) 13 reference
varieties. The data come from a randomised block
design conducted at four sites in one year. Under the
protocol of the experimental design each site was to
have been planted with the GM variety, the counterpart
variety and four reference varieties in three blocks of six
plots, but there were some deviations. The GM variety
was replicated three times at each site, and the conven-
tional counterpart variety three times at two of the sites,
but only twice at the other two sites. Each of three
reference varieties was planted at two sites, but each of
the remaining 10 reference varieties at one site only.
Most varieties had 3 replicates per site (but in some
cases only 2 or even 1). The data analysed here have
14-18 plots per site, for a total of 67 plots. It may be
noted that this experimental design is not ideal. For
example, the number of sites and the replication per site
were relatively low, and the conventional counterpart
was not included in all blocks. However, in spite of the
shortcomings of the experimental design the data were
found suitable for illustrating the statistical analysis.
For 15 of the 68 analytes considered (namely 13 fatty
acids, furfural and sodium) all results (or, in one case,
all but one) were below a given limit value. Without
further knowledge about the nature of this limit value
we simply refer to it as the limit of reporting. As there
was no variation in these results which could be used
for a comparative evaluation, they were omitted from
the further statistical analysis. Seven results in the
remaining set of 53 analytes were reported as less than
a given limit value (non-detects): six results for 16:1 pal-
mitoleic acid and one result for phytic acid. The pro-
blem seemed minor, and, although more advanced
van der Voet et al. BMC Biotechnology 2011, 11:15
http://www.biomedcentral.com/1472-6750/11/15
Page 18 of 20statistical methods exist to incorporate such results in
modelling, here the non-detects were simply set to half
the limit of reporting. Outliers were identified by visual
inspection of graphs showing the log-transformed
results for each of the three groups (GMO, counterpart,
reference). Outliers were identified for four analytes (see
[11] for details), and also the seven non-detects set to
half the limit of reporting were outlying. Outliers were
omitted from the further statistical analysis.
A small additional simulation study was performed to
investigate whether the observed number of significant
differences between GMO and counterpart (23) is large
under the null hypothesis that variation between geno-
types can be described by a normal distribution with
variance Vg on the logarithmic scale. Here we take for
Vg the quantifications as obtained with the mixed model
(Table 2). Under this null hypothesis and ignoring
further estimation error, differences d between any two
varieties would have a normal distribution with variance
2Vg. In 1000 iterations random values for d were
sampled from this distribution for all analytes, and a
two-sided t test at the 95% confidence level was per-
formed assuming that the sedGC;1 and the corresponding
degrees of freedom estimate from the actual experiment
were appropriate characterisations of residual error.
Over the 1000 iterations the average number of signifi-
cant test results was 36 (approximate 95% confidence
interval (30, 42)). Therefore, under a null hypothesis
describing equivalence between all the varieties, the
observed number of significant differences between
GMO and counterpart (23) is relatively small.
Differences between GMO and counterpart may not
be constant over sites. This was investigated by fitting
additional fixed terms ref_aside.site and ref_aside.geno-
typegroup.site in mixed model 1, and performing a
Wald test to obtain a p value for the significance of the
latter term. For 8 analytes the genotype by environment
(GxE) interaction was significant (p < 0.05), and geo-
metric means per site (not shown) may then help a
further interpretation of the results.
Availability and requirements
Programs implementing the proposed approach in the
GenStat and SAS statistical packages for the specific
example case data of this paper are available at http://
www.efsa.europa.eu/en/scdocs/doc/1250ax2.pdf. More
user-friendly and generally applicable software is under
development and will be made available on the EFSA
website later.
Acknowledgements
Work on this paper was performed in continuation of activities of the EFSA
GMO Panel working group Statistics. We would like to thank all members of
this working group and the GMO Panel for the stimulating discussions. Data
for the example given in this paper were made available by EFSA with the
approval of the applicant, for which we are grateful. We also thank all
responders in the public consultation of the first draft of the working group
report for sharing their insights.
Author details
1Wageningen University and Research centre, Biometris, P.O. Box 100, NL-
6700 AC Wageningen, Netherlands.
2Oaklands Barn, Lug’s Lane, Broome,
Norfolk NR35 2HT, UK.
3European Food Safety Authority, Largo N. Palli 5/A,
43121 Parma, Italy.
Authors’ contributions
HV developed the statistical model, performed the statistical analyses and
drafted the manuscript. JNP participated in the statistical model
development and the description of results. BA participated in the coding of
the model in SAS. CP provided the regulatory background and was
responsible for describing the position of EFSA. All authors contributed to
drafts, and read and approved the final manuscript.
Received: 4 November 2010 Accepted: 16 February 2011
Published: 16 February 2011
References
1. Mayer S, Stirling A: Finding a precautionary approach to technological
developments - Lessons for the evaluation of GM crops. Journal of
Agricultural & Environmental Ethics 2002, 15:57-71.
2. EFSA: Guidance document of the Scientific Panel on genetically modified
organisms for the risk assessment of genetically modified plants and derived
food and feed European Food Safety Authority, Parma; 2006.
3. Kok EJ, Kuiper HA: Comparative safety assessment for biotech crops.
Trends in Biotechnology 2003, 21:439-444.
4. König A, Cockburn A, Crevel RWR, Debruyne E, Grafstroem R,
Hammerling U, Kimber I, Knudsen I, Kuiper HA, Peijnenburg AACM,
Penninks AH, Poulsen M, Schauzu M, Wal JM: Assessment of the safety of
foods derived from genetically modified (GM) crops. Food Chem Toxicol
2004, 42:1047-1088.
5. Oberdoerfer RB, Shillito RD, de Beuckeleer M, Mitten DH: Rice (Oryza sativa
L.) containing the bar gene is compositionally equivalent to the
nontransgenic counterpart. Journal of Agricultural and Food Chemistry
2005, 53:1457-1465.
6. Hothorn LA, Oberdoerfer R: Statistical analysis used in the nutritional
assessment of novel food using the proof of safety. Regulatory Toxicology
and Pharmacology 2006, 44:125-135.
7. Hammond B, Lemen J, Dudek R, Ward D, Jiang C, Nemeth M, Burns J:
Results of a 90-day safety assurance study with rats fed grain from corn
rootworm-protected corn. Food and Chemical Toxicology 2006, 44:147-160.
8. Park H, Lee S, Jeong H, Cho S, Chun H, Back O, Kim D, Lillehoj HS: The
nutrient composition of the herbicide-tolerant green pepper is
equivalent to that of the conventional green pepper. Nutrition Research
2006, 26:546-548.
9. McNaughton JL, Roberts M, Rice D, Smith B, Hinds M, Schmidt J, Locke M,
Bryant A, Rood T, Layton R, Lamb I, Delaney B: Feeding performance in
broiler chickens fed diets containing DAS-59122-7 maize grain
compared to diets containing non-transgenic maize grain. Animal Feed
Science and Technology 2007, 132:227-239.
10. Herman RA, Storer NP, Phillips AM, Prochaska LM, Windels P: Compositional
assessment of event DAS-59122-7 maize using substantial equivalence.
Regulatory Toxicology and Pharmacology 2007, 47:37-47.
11. EFSA: Scientific Opinion on Statistical considerations for the safety
evaluation of GMOs. EFSA Journal 2010, 8:1250-59 [http://www.efsa.europa.eu].
12. FDA: Guidance for Industry - Statistical approaches to establishing
bioequivalence U.S. Department of Health and Human Services, Food and
Drug Administration, Center for Drug Evaluationand Research; 2001.
13. EMEA: Note for guidance on the investigation of bioavailability and
bioequivalence Document CPMP/EWP/QWP/1401/98, European Agency for
the Evaluation of Medicinal Products, Committee for Proprietary Medicinal
Products, London; 2001.
14. Ridley WP, Sidhu RS, Pyla PD, Nemeth MA, Breeze ML, Astwood JD: A
comparison of the nutritional profile of roundup ready corn event
NK603 to that of conventional corn (Zea mays L.). J Agric Food Chem
2002, 50:7235-7243.
van der Voet et al. BMC Biotechnology 2011, 11:15
http://www.biomedcentral.com/1472-6750/11/15
Page 19 of 2015. George C, Ridley WP, Obert JC: Composition of grain and forage from
corn rootworm-protected corn event MON 863 is equivalent to that of
conventional corn (Zea mays L.). J Agric Food Chem 2004, 52:4149-4158.
16. Reynolds TL, Nemeth MA, Glenn KC, Ridley WP, Astwood JD: Natural
variability of metabolites in maize grain: differences due to genetic
background. J Agric Food Chem 2005, 53:10061-10067.
17. Sha XY, Linscombe SD, Groth DE: Field evaluation of imidazolinone-
tolerant Clearfield rice (Oryza sativa L.) at nine Louisiana locations. Crop
Science 2007, 47:1177-1185.
18. Altman D, Bland JM: Absence of evidence is not evidence of absence.
British Medical Journal 1995, 311:485.
19. Altman D, Bland JM: Confidence intervals illuminate absence of evidence.
British Medical Journal 2004, 328:1016-1017.
20. Schuirmann DJ: A comparison of the two one-sided tests procedure and
the power approach for assessing the equivalence of average
bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 1987,
15:657-680.
21. Montgomery DC: Statistical Quality Control, a modern introduction Wiley;
2009.
22. Jones B, Jarvis P, Lewis JA, Ebbutt AF: Trials to assess equivalence: the
importance of rigorous methods. British Medical Journal 1996, 313:36-39.
23. Walters SJ: Consultants’ forum: should post hoc sample size calculations
be done? Pharmaceutical Statistics 2009, 8:163-169.
24. Tukey JW: Exploratory data analysis Addison-Wesley, Reading, Mass; 1977.
25. Tempelman RJ: Experimental design and statistical methods for classical
and bioequivalence hypothesis testing with an application to dairy
nutrition studies. Journal of Animal Science 2004, 82:E162-E172.
26. Basford KE, Cooper M: Genotype x environment interactions and some
considerations of their implications for wheat breeding in Australia.
Australian Journal of Agricultural Research 1998, 49:153-174.
27. Taylor ML, Hyun Y, Hartnell GF, Riordan SG, Nemeth MA, Karunanandaa K,
George B, Astwood JD: Comparison of broiler performance when fed
diets containing grain from YieldGard Rootworm (MON 863), YieldGard
Plus (MON 810 · MON 863), nontransgenic control, or commercial
reference corn hybrids. Poultry Science 2003, 82:1948-1956.
28. Taylor ML, Hartnell G, Nemeth M, Karunanandaa K, George B: Comparison
of broiler performance when fed diets containing corn grain with
insect-protected (corn rootworm and European corn borer) and
herbicide-tolerant (glyphosate) traits, control corn, or commercial
reference corn. Poultry Science 2005, 84:587-593.
29. Brown LD, Casella G, Hwang JTG: Optimal confidence sets,
bioequivalence, and the limaçon of Pascal. Journal of the American
Statistical Association 1995, 90:880-889.
30. Munk A, Pflüger R: 1-α equivalent confidence rules for convex
alternatives are α/2-level tests - with applications to the multivariate
assessment of bioequivalence. Journal of the American Statistical
Association 1999, 94:1311-1319.
31. Enot DP, Draper J: Statistical measures for validating plant genotype
similarity assessments following multivariate analysis of metabolome
data. Metabolomics 2007, 3:349-355.
32. Kenward MG, Roger JH: Small sample inference for fixed effects from
restricted maximum likelihood. Biometrics 1997, 53:983-997.
33. Spilke J, Piepho HP, Hu X: A simulation study on tests of hypotheses and
confidence intervals for fixed effects in mixed models for blocked
experiments with missing data. Journal of Agricultural, Biological and
Environmental Statistics 2005, 10:374-389.
doi:10.1186/1472-6750-11-15
Cite this article as: van der Voet et al.: A statistical assessment of
differences and equivalences between genetically modified
and reference plant varieties. BMC Biotechnology 2011 11:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van der Voet et al. BMC Biotechnology 2011, 11:15
http://www.biomedcentral.com/1472-6750/11/15
Page 20 of 20